Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Stevens-Johnson syndrome and HIV in children in Swaziland
Pediatric Infectious Disease Journal, Volume 32, No. 12, Year 2013
Notification
URL copied to clipboard!
Description
Background: Stevens-Johnson syndrome (SJS) can be a severe and lifethreatening reaction with many potential causes, including multiple medications used in HIV care and treatment. Specific risk factors, especially in children, are not currently well-understood. Methods: We describe a series of cases of SJS that occurred from 2006 to 2010 in an HIV-focused clinic in Mbabane, Swaziland. The electronic medical and pharmacy records of all pediatric patients 20 years old were reviewed to identify cases of SJS. Patient demographic, immunosuppression and outcome data were also collected. Results: A total of 19 cases of SJS were documented. Eighty-four percent of cases were attributed to nevirapine (NVP) exposure whereas the remaining cases were caused by cotrimoxazole (11%) and efavirenz (5%). Median symptom onset was 22 days after initiation of the offending medication (interquartile range = 14-25 days). At time of SJS, 84% had advanced or severe immunosuppression. Forty-two percent of patients required hospitalization, and no SJS-associated deaths were known to occur. Use of efavirenz was attempted in 8 NVP-associated cases after SJS resolution and was successful in all except 1. Conclusions: SJS occurrence was rare in this population, with the majority of cases being associated with NVP. All occurred within 32 days of medication initiation, providing a target window for intensified monitoring and anticipatory guidance. SJS can occur in children at any age, with any level of immunosuppression, and can occur during the lead-in dosing period of NVP. © 2013 Lippincott Williams &Wilkins.
Authors & Co-Authors
Dziuban, Eric J.
United States, Houston
Texas Children's Hospital
United States, Houston
Baylor College of Medicine
United States, New York
Bristol-myers Squibb
Hughey, Allison B.
United States, Houston
Texas Children's Hospital
Kochelani, Duncan
United States, Houston
Texas Children's Hospital
United States, New York
Bristol-myers Squibb
Draper, Heather R.
United States, Houston
Texas Children's Hospital
United States, Houston
Baylor College of Medicine
Schutze, Gordon E.
United States, Houston
Texas Children's Hospital
United States, Houston
Baylor College of Medicine
United States, New York
Bristol-myers Squibb
Statistics
Citations: 6
Authors: 5
Affiliations: 3
Identifiers
Doi:
10.1097/INF.0b013e31829ec8e5
ISSN:
15320987
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Eswatini